Assessment and prognostic value of the European leukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Blood

Volumn 119, Issue 6, 2012, Pages 1363-1369

  Alvarez Larrán, Alberto ^a   Pereira, Arturo ^b   Cervantes, Francisco ^b   Arellano Rodrigo, Eduardo ^b   Hernández Boluda, Juan Carlos ^c   Ferrer Marín, Francisca ^d   Angona, Anna ^a   Gómez, Montse ^c   Muiña, Begoña ^d   Guillén, Helga ^e   Teruel, Anabel ^c   Bellosillo, Beatriz ^a   Burgaleta, Carmen ^e   Vicente, Vicente ^d   Besses, Carles ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPEAN LEUKEMIANET CRITERIA; FEMALE; HEMATOCRIT; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84856866188     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-387787     Document Type: Article

References (23)

1. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107(11):4214-4222. (Pubitemid 43801343)
2. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13): 4272-4290. (Pubitemid 35429665)
3. Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost. 2007;33(4):321-329. (Pubitemid 46878104)
4. Tefferi A. Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, riskstratification, and management. Am J Hematol. 2011;86(3):292-301.
5. Berk P,Wasserman LR, Fruchtman S, Goldberg J. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin BI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA: Saunders; 1995:166-192.
6. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90(9):3370-3377. (Pubitemid 27473405)
7. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907-3913.
8. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009; 113(20):4829-4833.
9. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961-963.
10. Barbui T, Barosi G, Birgegard G, et al. European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
11. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
12. Dickman P, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23(1):51-64. (Pubitemid 38072106)
13. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
14. Jann B. Splitting time-span records with categorical time-varying covariates. Stata J. 2004;4(2): 221-222.
15. Coviello VBN. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004; 4(2):103-112.
16. Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116(7):1051-1055.
17. Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol. 2011;152(1):81-88.
18. Di Nisio M, Barbui T, Di Gennaro L, et al. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249-259.
19. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978; 2(8102):1219-1222. (Pubitemid 9071903)
20. Crisà E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with antithrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691-699.
21. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007; 109(6):2446-2452. (Pubitemid 46425887)
22. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670. (Pubitemid 40446255)
23. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354-138.